CLDX GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
Celldex Therapeutics Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Visit www.celldex.com.
Current Price
$31.34
-3.42%Profile
Valuation (TTM)
Market Cap$2.09B
P/E-7.35
EV—
P/B3.96
Shares Out66.57M
P/Sales2408.99
Revenue$866000.00
EV/EBITDA—
Celldex Therapeutics Inc (CLDX) Quality Analysis
CLDX Profitability
Profitability trend analysis coming soon
CLDX Growth
Growth trend analysis coming soon
CLDX Financial Health
Financial health indicators coming soon
CLDX Quality & Fundamental Analysis
Celldex Therapeutics Inc (CLDX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. This quality analysis page evaluates Celldex Therapeutics Inc's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Celldex Therapeutics Inc has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of -32753.58% and a return on equity (ROE) of -53.81%. Return on assets (ROA) stands at -48.65%.
The debt-to-equity ratio is 0.00, with a current ratio of 10.49. Operating margin is -18599.81%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Celldex Therapeutics Inc is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.